Viking Therapeutics CFO logs RSU vesting, tax sale

Viking Therapeutics, Inc. CFO Greg Zante reported two stock transactions.

Rhea-AI Filing Summary

Viking Therapeutics, Inc. CFO Greg Zante reported two stock transactions. On July 28, 2026 he acquired 31,667 shares of common stock at no cost when 33.33% of a performance restricted stock unit award granted January 3, 2023 vested after a non‑financial goal was met. On July 29, 2026, 21,217 shares were automatically sold on a non‑discretionary basis solely to satisfy tax withholding obligations, at a weighted‑average price of $33.4704 per share in multiple trades between $33.30 and $33.805.

Insider Trade Summary

Net Seller: 21,217 shares

Net Sell 2 txns

Insider ZANTE GREG

Role Chief Financial Officer

Sold 21,217 shs ($710K)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.00001 per share F3, F4	21,217	$33.4704	$710K
Grant/Award	Common Stock, par value $0.00001 per share F1, F2	31,667	$0.00	$0.00

Holdings After Transaction: Common Stock, par value $0.00001 per share — 212,204 shares (Direct)

Footnotes (4)

1. F1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
2. F2. Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan
3. F3. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.

Key Figures

RSU Shares Vested: 31,667 shares Vested Portion of Award: 33.33% RSU Grant Date: January 3, 2023 +5 more

8 metrics

RSU Shares Vested 31,667 shares Common shares acquired at no cost on July 28, 2026 upon RSU vesting

Vested Portion of Award 33.33% Portion of performance RSU award that vested July 28, 2026

RSU Grant Date January 3, 2023 Grant date of the performance restricted stock unit award

Shares Sold for Taxes 21,217 shares Common shares sold July 29, 2026 to satisfy tax withholding

Weighted‑Average Sale Price $33.4704 per share Average price for 21,217 shares sold July 29, 2026

Sale Price Range $33.30–$33.805 per share Price range for multiple sale transactions on July 29, 2026

2014 ESPP Shares 11,055 shares Shares acquired May 20, 2024 under 2014 Employee Stock Purchase Plan

2024 ESPP Shares 808 shares Shares acquired May 20, 2026 under 2024 Employee Stock Purchase Plan

Key Terms

performance restricted stock unit award, weighted average price, non-discretionary basis, tax withholding obligations, +1 more

5 terms

performance restricted stock unit award financial

"The reported securities were subject to a performance restricted stock unit award"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

non-discretionary basis financial

"These shares were automatically sold on a non-discretionary basis solely to satisfy"

tax withholding obligations financial

"sold on a non-discretionary basis solely to satisfy certain tax withholding obligations"

Employee Stock Purchase Plan financial

"shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Viking Therapeutics (VKTX) CFO Greg Zante report?

He reported a performance RSU vesting and a related tax sale. On July 28, 2026, 31,667 shares vested and were acquired at no cost. On July 29, 2026, 21,217 shares were automatically sold to cover tax withholding at a weighted‑average price of $33.4704.

How many Viking Therapeutics (VKTX) shares did the CFO sell and at what price?

The CFO reported selling 21,217 shares of common stock on July 29, 2026. The weighted‑average sale price was $33.4704 per share, with individual trades executed in a range between $33.30 and $33.805, solely to satisfy tax withholding obligations.

What is the performance RSU award mentioned for Viking Therapeutics (VKTX)?

The report describes a performance restricted stock unit award granted on January 3, 2023. On July 28, 2026, 33.33% of this award vested after a non‑financial performance goal was achieved, resulting in the acquisition of 31,667 shares of Viking Therapeutics common stock.

Were the Viking Therapeutics (VKTX) CFO’s share sales discretionary?

No. The 21,217 shares sold on July 29, 2026 were disposed of on a non‑discretionary basis. The disclosure states they were automatically sold solely to satisfy tax withholding obligations arising from the issuance of shares upon vesting of the performance RSU award.

What additional Viking Therapeutics (VKTX) shares did the CFO obtain through employee stock purchase plans?

Reported holdings include shares from two employee stock purchase plans: 11,055 shares acquired on May 20, 2024 under the 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 under the 2024 Employee Stock Purchase Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/29/2026 - 08:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZANTE GREG

(Last) (First) (Middle)

C/O VIKING THERAPEUTICS, INC.

9920 PACIFIC HEIGHTS BLVD, SUITE 350

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.00001 per share	07/28/2026		A		31,667(1)	A	$0	233,421(2)	D
Common Stock, par value $0.00001 per share	07/29/2026		S		21,217(3)	D	$33.4704(4)	212,204	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.

2. Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan

3. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.

	/s/ Michael Morneau, as Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)